What Lexicon Pharmaceuticals, Inc. does.

We are a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. We are devoting most of our resources to the research and development of our most advanced drug candidates and the commercialization of our approved drug, INPEFA ® (sotagliflozin):

• We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for hypertrophic cardiomyopathy, or HCM, and are conducting the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication.

• We are separately pursuing regulatory approval of ZYNQUISTA ® (sotagliflozin) as a treatment for type 1 diabetes. The U.S. Food and Drug Administration, or FDA, issued complete response letters regarding our New Drug Application, or NDA, for ZYNQUISTA in type 1 diabetes in March 2019 and December 2024. At our request, the FDA has issued a public Notice of Opportunity for Hearing, or NOOH, on whether there are grounds for denying approval of our NDA and those proceedings are ongoing.

Revenue and profit, by fiscal year.

More on LXRX.

• Lexicon Pharmaceuticals, Inc. summary
• Lexicon Pharmaceuticals, Inc. financial statements
• Lexicon Pharmaceuticals, Inc. key metrics
• Lexicon Pharmaceuticals, Inc. health scores and style box
• Lexicon Pharmaceuticals, Inc. earnings
• Lexicon Pharmaceuticals, Inc. dividends
• Lexicon Pharmaceuticals, Inc. valuation
• Lexicon Pharmaceuticals, Inc. ownership and insiders
• Lexicon Pharmaceuticals, Inc. peers

Figures from Lexicon Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.